Alligator Bioscience AB Stock price

Equities

ATORX

SE0000767188

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 07:59:42 2024-03-28 am EDT 5-day change 1st Jan Change
0.994 SEK +2.26% Intraday chart for Alligator Bioscience AB +1.95% +44.27%
Sales 2024 * 266M 24.89M Sales 2025 * 136M 12.69M Capitalization 640M 59.81M
Net income 2024 * - 0 Net income 2025 * -72M -6.73M EV / Sales 2024 * 1.29 x
Net cash position 2024 * 297M 27.77M Net cash position 2025 * - 0 EV / Sales 2025 * 4.71 x
P/E ratio 2024 *
-1.82 x
P/E ratio 2025 *
-3.05 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.64%
More Fundamentals * Assessed data
Dynamic Chart
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 CI
Transcript : Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan MT
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan MT
Alligator Bioscience to Trim Workforce Amid Restructuring Program MT
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation CI
Transcript : Alligator Bioscience AB - Special Call
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer CI
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody MT
Transcript : Alligator Bioscience AB - Analyst/Investor Day
Certain Ordinary Shares of Alligator Bioscience AB are subject to a Lock-Up Agreement Ending on 9-NOV-2023. CI
Alligator Bioscience AB Appoints Bertil Brinck as Chairman of the Nomination Committee CI
Transcript : Alligator Bioscience AB, Q3 2023 Earnings Call, Oct 26, 2023
More news
1 week+0.31%
Current month-11.89%
1 month-12.05%
3 months+39.91%
6 months+136.52%
Current year+41.94%
More quotes
1 week
0.96
Extreme 0.959
1.03
1 month
0.95
Extreme 0.954
1.17
Current year
0.66
Extreme 0.661
1.57
1 year
0.34
Extreme 0.34
1.57
3 years
0.34
Extreme 0.34
7.20
5 years
0.34
Extreme 0.34
27.40
10 years
0.34
Extreme 0.34
40.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 21-05-31
Director of Finance/CFO 60 20-08-31
Chief Tech/Sci/R&D Officer 56 22-01-31
Members of the board TitleAgeSince
Director/Board Member 63 19-05-08
Chairman 70 16-12-31
Director/Board Member 73 22-05-08
More insiders
Date Price Change Volume
24-03-28 0.994 +2.26% 700 077
24-03-27 0.972 -1.02% 1,522,143
24-03-26 0.982 -0.51% 1,205,807
24-03-25 0.987 -1.50% 1,197,260
24-03-22 1.002 +2.77% 1,376,463

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 05:32 am EDT

More quotes
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.972 SEK
Average target price
2.3 SEK
Spread / Average Target
+136.63%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Alligator Bioscience AB - Nasdaq Stockholm